Search - tctmd.com

Displaying 1 - 20 of 56

Sort: Relevancy | Date

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Michael O'Riordan

December 03, 2018

News Daily News

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

Michael O'Riordan

November 23, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Michael O'Riordan

November 15, 2018

News Conference News AHA 2018

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Shelley Wood

November 11, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News AHA 2018

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Shelley Wood

November 10, 2018

News Daily News

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

Michael O'Riordan

November 06, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

L.A. McKeown

October 16, 2018

News Daily News

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Michael O'Riordan

October 15, 2018

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

News Daily News

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

Todd Neale

September 13, 2018

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

Shelley Wood

August 26, 2018

News Daily News

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

Todd Neale

August 17, 2018

News Daily News

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

Caitlin E. Cox

August 15, 2018

News Daily News

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Michael O'Riordan

August 13, 2018

Advertisement

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Benefits of Statins Only Exceed Harms at Higher 10-Year Risk Thresholds, Study Suggests

Angina Without Obstructive Stenosis: No Longer a ‘Black Box’ Mystery, Say Experts

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Alirocumab Should Be Priced at $6,300 Annually: ODYSSEY Cost-Effectiveness Study

Novel Inhibitor of Apolipoprotein(a) Production Lowers Lp(a) in Phase II Study

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

VITAL: No Benefits to Vitamin D and Omega-3s in Reducing Major CV Events, Cancer

Statins Provide No Clinical Benefit When Coronary Calcium Is Zero, Study Shows

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

CAC Scoring Is Predictive of Risk Across Races and Ethnicities

Elevated Lp(a), Even in Statin-Treated Patients, Linked With Higher CVD Risks

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Lack of Short-term Cancer Risk With Tainted Valsartan ‘Reassuring’

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

ADAPT-DES: High On-Aspirin Platelet Reactivity Not Related to PCI Outcomes

In Type 2 Diabetes, Five Risk Factor Targets Keep MI, Stroke, and Death in Check

New CV Risk Model Predicts Recurrent MACE at 1 Year in Post-MI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content